Brind.
  1. Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction.

Merck acquired Verona's Ohtuvayre asset, which is subject to Phase III trials in China.

2 reports, 2 independent Updated Aug 11
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Merck acquired Verona's Ohtuvayre asset, which is subject to Phase III trials in China.

Who's involved

What this event is mainly about
MerckVerona

How it developed

Newest first. Tap a step to see who reported it.
  1. Merck acquired Verona's Ohtuvayre asset, accelerating COPD drug growth.1 source
  2. FDA approved Ohtuvayre for COPD, and the acquisition allowed the launch of Winrevair.1 source

Keep exploring

Part of

Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Zacks Small Cap ResearchLGND: Getting In Tune with MedTech By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and opera
  • Motley FoolDoes This Move Make Merck Stock a Buy? Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition that will help it achieve that goal